Coherus Oncology Inc

Aperta

SettoreSettore sanitario

1.42 -1.39

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.42

Massimo

1.45

Metriche Chiave

By Trading Economics

Entrata

-279M

-38M

Vendite

-438K

12M

P/E

Media del settore

3.509

50.958

EPS

-0.25

Margine di Profitto

-308.197

Dipendenti

145

EBITDA

9.3M

-34M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+468.97% upside

Dividendi

By Acuity

Utili prossimi

6 ago 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-31M

228M

Apertura precedente

2.81

Chiusura precedente

1.42

Notizie sul Sentiment di mercato

By Acuity

50%

50%

137 / 342 Classifica in Healthcare

Coherus Oncology Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

29 giu 2026, 23:31 UTC

News
Social Media

Comcast shares are higher in after-market trading amid reports of a potential expansion into video games and plans for AI-focused data centers.

29 giu 2026, 23:26 UTC

Social Media
News

Micron Technology shares are lower after hours amid mixed sentiment and legal challenges over alleged memory chip production manipulation, despite revenue rising to $41.5 billion.

29 giu 2026, 23:16 UTC

News

O'Reilly Automotive Inc shares are lower in after-market hours, following a slight decline since Monday's close amid a ranking rise in the S&P 500.

29 giu 2026, 23:11 UTC

News
Correlated Moves

The GBP/HKD is higher today, reaching the upper end of its daily range amid market volatility from renewed U.S.-Iran hostilities ahead of talks in Doha.

29 giu 2026, 23:06 UTC

News
ETF Constituents

Investor caution persists amid U.S.-Iran tensions, with the Vanguard Growth ETF showing little change in after-market trading. Microsoft leads contributors with a 0.85% return.

29 giu 2026, 23:06 UTC

News

Regeneron Pharmaceuticals will join the FDA's PreCheck Pilot Program to enhance domestic drug manufacturing. Shares are trading lower in after-market hours.

29 giu 2026, 23:06 UTC

News

U.S. West Texas Intermediate futures rose to $70.51 per barrel after a U.S.-Iran agreement eased tensions, supporting United States Oil Fund LP in after-market trading.

29 giu 2026, 23:06 UTC

News

Piper Sandler initiated coverage of PayPal with a Neutral rating and a price target of $42.00. Shares were roughly flat in after-market hours.

29 giu 2026, 23:02 UTC

News
ETF Constituents
Macro News
Correlated Moves

The Dow Jones Industrial Average closed above 52,000, driven by a rebound in technology stocks. The Vanguard Information Technology ETF showed little change in after-market hours.

29 giu 2026, 20:07 UTC

News

The USD/THB is lower as optimism grows over U.S.-Iran talks after military exchanges. The asset remains above its 20-day moving average.

29 giu 2026, 20:07 UTC

News
Correlated Moves

Ethereum is trading higher, supported by easing Middle East tensions and Bitmine's acquisition of 27,084 ETH, raising its total holdings to 5.7 million ETH.

29 giu 2026, 20:07 UTC

Correlated Moves
Social Media
News
ETF Constituents

Positive sentiment for the SPDR Dow Jones Industrial Average ETF Trust follows a halt in U.S.-Iran military actions, easing geopolitical tensions and supporting stock futures.

29 giu 2026, 20:07 UTC

Social Media
News

Intel shares are higher as Cantor Fitzgerald raises its price target to $150, indicating a recovery from early session lows.

29 giu 2026, 20:07 UTC

News

Positive economic indicators and easing U.S.-Iran tensions boost the Nikkei 225 Index higher during after-market hours, with retail sales rising 5.3% year-on-year.

29 giu 2026, 20:07 UTC

News

USD/ZAR is trading lower as optimism over U.S.-Iran talks eases energy supply concerns. This marks the third consecutive session of declines.

29 giu 2026, 20:07 UTC

News
Correlated Moves

USD/PLN is lower today, influenced by a decline in the US Dollar Index and improved sentiment from U.S.-Iran relations.

29 giu 2026, 20:07 UTC

News
Correlated Moves

Gold prices are lower today amid renewed U.S.-Iran tensions and potential Federal Reserve interest rate hikes. Crude oil's rise may diminish gold's safe-haven appeal.

29 giu 2026, 20:07 UTC

Social Media
Correlated Moves
News

Trading lower amid a declining US Dollar Index; JPMorgan's blockchain impact.

29 giu 2026, 20:07 UTC

News
Correlated Moves

USD/DKK is trading lower as the US Dollar Index declines. Renewed optimism over U.S.-Iran relations is also influencing market sentiment.

29 giu 2026, 20:07 UTC

Correlated Moves
News

USD/CZK declines amid a falling US Dollar Index, reflecting volatility in today's session. The pair remains above its 20-day moving average.

29 giu 2026, 20:06 UTC

News
Correlated Moves

Microchip Technology Inc is rising amid positive momentum in the semiconductor sector, supported by strength in the broader market and a favorable analyst consensus.

29 giu 2026, 20:06 UTC

Correlated Moves
News

Gold prices are lower today amid renewed U.S.-Iran tensions and concerns over potential Federal Reserve interest rate hikes. Crude oil prices have surged as well.

29 giu 2026, 20:06 UTC

Correlated Moves
News

USD/NOK is trading lower amid optimism over U.S.-Iran relations, despite remaining above its 20-day moving average. The US Dollar Index has also declined.

29 giu 2026, 20:04 UTC

ETF Constituents
Correlated Moves
Social Media
News

SPDR S&P 500 ETF Trust advances as U.S. and Iran agree to halt military strikes, boosting market sentiment ahead of a diplomatic summit in Doha.

29 giu 2026, 20:04 UTC

ETF Constituents
Social Media
News
Correlated Moves

Invesco QQQ Trust rises as U.S.-Iran tensions ease, boosting market sentiment. Strong performance from Amazon and Tesla supports the ETF's advance since Friday.

29 giu 2026, 20:03 UTC

Social Media
News

Tesla Inc. shares are higher today amid positive delivery forecasts and the closure of an NHTSA investigation into power steering issues.

29 giu 2026, 20:03 UTC

News
Correlated Moves

Alphabet Inc shares are higher today, supported by increased call volume and a favorable Supreme Court ruling easing regulatory concerns for tech companies.

29 giu 2026, 20:03 UTC

News
Correlated Moves
Social Media
ETF Constituents

The Communication Services Select Sector SPDR Fund is gaining today, driven by strong performances from GOOGL and META amid a broader tech rally.

29 giu 2026, 20:03 UTC

Social Media
News

GameStop is pursuing a $56 billion bid for eBay, despite rejection. eBay shares are trading higher amid acquisition discussions and technical platform issues.

29 giu 2026, 20:03 UTC

Correlated Moves
Social Media
News

Amazon.com Inc. is advancing, supported by a market rally and a new partnership with Park Ha Biological to enhance personal care product offerings.

Confronto tra pari

Modifica del prezzo

Coherus Oncology Inc Previsione

Obiettivo di Prezzo

By TipRanks

468.97% in crescita

Previsioni per 12 mesi

Media 8.25 USD  468.97%

Alto 12 USD

Basso 4 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Coherus Oncology Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

5 ratings

5

Acquista

0

Mantieni

0

Vendi

Sentiment

By Acuity

137 / 342 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
help-icon Live chat